 Meloxicam has been found to be effective at reducing depression symptoms and rodents exposed to chronic restraint stress. This is due to its ability to reduce corticosterone levels, increase norepinephrine, serotonin, and dopamine levels in the hippocampus, and reduce oxidative stress and inflammation. Additionally, it increases the expression of the antioxidant enzyme NRF2 and reduces the expression of the prooxidant enzymes NOX1 and NOX4. This article was authored by Haney H. Arab, Ali Kams, Mostafa K. Muhammad, and others.